1

# 1 The incidence and mortality of COVID-19 related TB disease in Sub-Saharan Africa: A

# 2 systematic review and meta-analysis

3 Jacques L Tamuzi<sup>1\*</sup>, Gomer Lulendo<sup>2</sup>, Patrick Mbuesse<sup>2</sup>, Peter S. Nyasulu<sup>1,3\*</sup>

# 4 Author affiliations

<sup>1</sup>Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of

- 6 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- <sup>7</sup> <sup>2</sup>Africa Centre for HIVAIDS management, Stellenbosch University, Cape Town, South

8 Africa

9 <sup>3</sup>Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health

10 Sciences, University of the Witwatersrand, Johannesburg, South Africa

11

\* Corresponding Author: Jacques L. Tamuzi Division of Epidemiology, Faculty of
 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Emails:
 <drjacques.tamuzi@gmail.com>

15 Jacques L Tamuzi (ORCID): 0000-0003-1070-1962

16 Peter S. Nyasulu (ORCID): 0000-0003-2757-0663

17

- 19
- 20

2

21

#### 22 Abstract

### 23 Background

24 Coronavirus disease 2019 (COVID-19) is also associated with other co-morbidities in people 25 who have previously or currently have pulmonary tuberculosis (PTB). PTB is a risk factor for 26 COVID-19, both in terms of severity and mortality, regardless of HIV status. However, there 27 is less information available on COVID-19 and PTB in terms of incidence and mortality rates 28 in Sub-Saharan Africa (SSA), a high-burden TB region. This systematic review provided a 29 data synthesis of available evidence on COVID-19/PTB incidence and case fatality rates, as 30 well as mortality rates found in clinical and post-mortem COVID-19/PTB diagnostics in 31 SSA.

### 32 Methods

We conducted an electronic search in the PubMed, Medline, Google Scholar, Medrxix, and COVID-19 Global literature on coronavirus disease databases for studies involving COVID-19 and PTB in Sub-Saharan Africa. The primary outcomes were the incidence proportion of people with COVID-19 who had current or previous PTB, as well as the case fatality rate associated with COVID-19/PTB. Based on methodological similarities in the included random effect model studies, the combination method was developed using Stata version 16 and Prometa 3 software. We also performed sensitivity analysis and meta-regression.

#### 40 **Results**

From the 548 references extracted by the literature search, 25 studies were selected and included in the meta-analysis with a total of 191, 250 COVID-19 infected patients and 11,

3

43	480 COVID-19 deaths. The pooled COVID-19/PTB incidence was 3% [2%-5%] and a case
44	fatality rate of 13% [4%-23%]. The pooled estimates for case fatality rate among COVID-
45	19/PTB were 7% [1%-12%] for clinical PTB diagnostic and 25% [3%-47%] for post-mortem
46	PTB diagnostic. Previous TB had the highest incidence and fatality rates with 46 [19-73] per
47	1, 000 population and 8% [3%-19%], respectively. Meta-regression model including the
48	effect sizes and cumulative COVID-19 cases ( $P=0.032$ ), HIV prevalence ( $P=0.041$ ), and TB
49	incidence ( $P=0.002$ ) to explain high heterogeneity between studies.

# 50 Conclusion

To summarize, the incidence of TB associated with COVID-19 is higher in SSA, as are the case fatality rates, when compared to the rest of the world. However, because the postmortem TB diagnostic was higher, COVID-19 associated with TB may have been underreported in studies conducted in SSA. To confirm COVID-19/TB incidence and case fatality rates in SSA, large-scale cohort studies that adequately clear tools on previous and/or current TB diagnostic tools are required.

57

58	Key words:	COVID-19,	PTB, Incidenc	e rate, Case fatality	y rate, sub-Saharan Africa
----	------------	-----------	---------------	-----------------------	----------------------------

59 Review registration: PROSPERO (CRD42021233387)

- 60
- 61
- 62

63

4

65			
66			
67			
68			

#### 69 **1. Background**

70 The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and 71 mortality all over the world, with total confirmed cases more than 634 million globally and 6 million deaths in 25 November 2022 [1]. In the African region, more than 9 million 72 73 confirmed cases are already recorded, among them, 174, 858 deaths on 25 November 74 2022[1]. Though it is reported that the African region showed a decreasing trend in the 75 number of deaths over the past several weeks compared to other World Health Organization 76 (WHO) regions [1]. The age groups at highest risk of severe COVID-19 disease and death 77 (those >60 years old) [2-4] may be proportionately less in many sub-Saharan Africa (SSA) 78 countries than in other parts of the world [4]. In contradistinction to potential health 79 vulnerabilities, sub-Saharan African countries could be "protected" from COVID-19 80 mortality by an age structure differing significantly from countries where morbidity and 81 mortality have been particularly high such as Italy, Spain, the United States, and in Hubei 82 Province in China [5-7].

On the other hand, COVID-19 is associated with other co-morbidities in patients with previous or current pulmonary tuberculosis (PTB) [8]. A recent review found that PTB is a risk factor for COVID-19 regardless of HIV status, both in terms of severity and mortality [8]. Geographically, most people who developed tuberculosis (TB) live in South-East Asia (44%), Africa (25%), and the Western Pacific (18%) [9]. It is estimated that low- and middleincome countries, including SSA, account for 94% of all TB infections and deaths [10]. An

5

89 observational study found that people with latent or active tuberculosis were more vulnerable 90 to infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [11]. 91 This study found infection with Mycobacterium tuberculosis to be a more common co-92 morbidity for COVID-19 (36%) [11]. They also found Mycobacterium tuberculosis co-93 infection to be linked to more severe COVID-19 and more rapid progression [12]. Another 94 study conducted in Zambia revealed that 31.4% of post-mortem PTB diagnoses in COVID-19 95 deaths [13]. In countries where PTB risk factors for mortality are highly prevalent among 96 young individuals (poverty, overcrowding, diabetes mellitus, smoking, alcohol and substance 97 abuse, HIV co-infection, among others), particularly in the presence of drug resistance and 98 difficult access to diagnosis (delayed diagnosis) [14, 15], COVID-19 incidence and mortality 99 associated with PTB may be hypothesized as significant. However, COVID-19 associated 100 with previous, current, or both PTB has been lower in high-burden TB countries. Both active 101 and previous history of PTB may play a deleterious synergism SARS-CoV-2, increasing then 102 the risk of COVID-19 associated mortality, and for patients with PTB may increase the 103 severity of COVID-19 and of death due to chronic lung disease and immunosuppression [8]. 104 This may contribute to higher-than-expected mortality in high PTB-burden regions such as 105 SSA.

Therefore, there is less information available on COVID-19 associated with PTB from the point of view of incidence and fatality rates in SSA. This systematic review served to provide data synthesis of available evidence on COVID-19/TB incidence and case fatality rates, and case fatality rates found in clinical and post-mortem COVID-19/TB diagnostics in SSA.

110 **2**. **Results** 

#### 111 **2.1. Search results**

6

From the 548 references extracted by the literature search (Figure 1), 64 articles were analysed, among which 33 were excluded with reasons, and 25 studies were selected and included in the meta-analysis and six studies were excluded as they were study protocols. We included a total of 191, 250 COVID-19 infected patients and 11, 480 COVID-19 deaths (Supplemental material Table 1).
The selected articles reported data from South Africa (n = 9), Nigeria (n = 4), Democratic Republic of Congo (n = 2), Angola (n=1), Uganda (n = 1), Zambia (n = 5), Ethiopia (n=2)

and Kenya (n = 1) (Figure 2 and Supplemental material Table 1)

120 **2.2. Included studies** 

Twenty-five studies were included for quantitative analysis. All the studies analysed clinical characteristics and co-morbidities of COVID-19 patients in SSA. Among them, twenty studies included the incidence proportion of COVID-19 associated with PTB [16-35], and nine studies included the case fatality rate of COVID-19 associated with TB [13, 16, 26, 29, 34, 36-39].

126 The minimum age for the study population was 13 years and the maximum was 72 years. 127 Incidence and case fatality of PTB associated with COVID-19, stratified by sex were not 128 obvious as all the studies included common co-morbidities associated with COVID-19 129 without sex stratification. The median study duration was 15 months (ranging, from 4 months 130 to 45 years) and the study period ranged from 2020 to 2021. Eleven studies used retrospective 131 case identification [13, 26-33, 36, 39], six prospective case identification [16-20, 35], and 132 three were case series [20, 37, 38], three Cross-sectional studies [22-24], one cross-sectional 133 and retrospective cohort study [34] and one case-control study [25] (Supplementary 134 material Table 1).

135 **2.3. Study quality** 

7

136 The Newcastle-Ottawa scale (NOS) was used to determine the methodological validity of 137 included research for determining the consistency of cohort, case-control, and descriptive 138 studies in meta-analyses. The three essential components of this strategy are range, 139 comparability, and exposure (Supplementary material Table 2 and Supplementary 140 material method 3). For case-control and cohort studies, the NOS employs a star system 141 with ratings ranging from 0 to 9 (Supplementary material Table 2 and Supplementary 142 **material method 3**). We considered a study with a higher score than the six of each type of 143 study to be a high-quality study because the criteria for determining whether a study is a high 144 or poor quality are unknown. Two studies scored eight, five scored seven, eight scored six, 145 five scored five, and one scored four. Supplementary material Table 2 shows the NOS 146 scores for the studies that were included.

### 147 **2.4. Outcomes measurement**

148 In this review, we defined the incidence proportion as the number of new cases of COVID-19 149 associated with PTB over the total number of people in the population at risk for having 150 COVID-19 during a specified period (**Supplementary material method 3**). The case fatality 151 rate was defined as the total number of new deaths due to COVID-19 associated with TB 152 divided by the total number of COVID-19 associated with PTB. The incidence and case 153 fatality rates were summarized as specific period cases per 100 or 1, 000 (Supplementary 154 material method 3). The incidence and case fatality rates of COVID-19 associated with TB 155 were our primary outcomes. The incidence and case fatality rates of COVID-19 associated 156 with previous and current TB were the secondary outcomes.

#### 157 **2.5. Meta-analysis and meta-regression**

### 158 2.5.1. Incidence proportion of COVID-19 associated with TB

8

159 In total, 20 studies were identified for the incidence proportion of COVID-19 associated with

- 160 PTB in SSA. The pooled RR-P [95% CI] was 3% [2%-5%] (Figure 3). The test for
- heterogeneity was statistically significant with ( $l^2 = 99.76 \text{ P} < 0.0001$ ) (Figure 3).

### 162 2.5.2. Incidence proportion of COVID-19 associated with current and previous TB

- 163 Only six of the twenty studies included in the pooled result of the incidence proportion rate of
- 164 COVID-19 associated with TB clearly classified current and previous TB. The pooled current
- and previous TB incidence proportion rate was 28 [13-43] per 1,000 population (Figure 4).
- 166 Previous TB had the highest incidence proportion rate with 46 [19-73] per 1,000 population
- 167 (Figure 4). The incidence proportion rates for current TB and current and past TB were 14
- 168 [6-22] and 10 [9-11] per 1,000, respectively (**Figure 4**).

### 169 2.5.3. Case fatality rate of COVID-19 associated with TB

We identified ten studies [13, 16, 17, 26, 29, 34, 36-39] meeting the inclusion criteria relating mortality proportion of COVID-19 associated with PTB in SSA. The pooled RR-P [95%CI] estimates for mortality proportion among patients with COVID-19 associated with TB were 7% [1%-12%] for clinical PTB diagnostic and 25% [3%-47%] for post-mortem PTB diagnostic. The overall pooled RR-P was 13% [4%-23%] (**Figure 5**). Heterogeneity between studies was high ( $I^2 = 98.82$ , P <0.001) however, the test for subgroup analysis did not show any difference between the groups (**Figure 5**).

### 177 2.5.4. Case fatality rate of COVID-19 associated with current and previous TB

In the meta-analysis of the case fatality rate of COVID-19 associated with current and previous TB, four studies clearly categorized clinical diagnoses of current and previous TB. Previous TB had the highest case fatality rate of 8% [3%-19%] (**Figure 6**). Current TB and current and past TB had a case fatality of 3% [1%-4%] and 1% [1%-1%], respectively (**Figure 6**).

9

#### 183 **2.5.3. Meta-regression**

184 We built a multivariate meta-regression model including cumulative COVID-19 cases, HIV 185 prevalence, and TB incidence to explore heterogeneity between studies. People living with 186 HIV (all ages), TB incidence rate, and cumulative COVID-19 cases were (7, 800, 000; 360 in thousands; 3, 533, 106) for South Africa, (1, 700, 000; 440 in thousands; 231, 413) for 187 188 Nigeria, (1 700 000; 59 in thousands, 221, 880) for Zambia, (1, 500, 000; 157 in thousands; 189 382, 371) for Ethiopia, (510, 000; 278 in thousands; 70, 059) for the Democratic Republic of 190 Congo, (1, 400, 000; 140 in thousands; 270, 899) for Kenya, (340, 000; 112 in thousands; 65, 191 938) for Angola and (1, 400, 000; 253 in thousands; 130, 178) for Uganda [1, 40, 41]. This 192 model showed that the variability across studies was explained by COVID-19 cumulative 193 cases by countries (P=0.032), HIV prevalence (P=0.041), and TB incidence (P=0.002).

#### 194 **2.5.4.** Publication bias

195 Egger's and Mazumdar's rank correlation test and Begg's funnel plot were used to evaluate 196 publication bias quantitatively and qualitatively respectively. Asymmetry was found in the 197 plot including COVID-19/TB incidence proportion (Figure 7). Both Egger's and 198 Mazumdar's rank correlation tests did not exhibit obvious publication bias in different studies 199 included in the review because the P-values of both tests for COVID-19/TB incidence rate 200 were (-1.10, P = 0.285) and (-0.26, P = 0.795), respectively. Furthermore, P-values of both 201 tests for COVID-19/TB mortality rate were [Egger's test (t = 0.49, p = 0.642)] 0.173 and 202 [Begg and Mazumdar's rank correlation test (z = -0.83, p = 0.404)], respectively.

### 203 2.5.5. Sensitivity analysis

For all the studies including in COVID-19/TB incidence and case fatality rate in SSA, sensitivity analysis was performed by sequential omission of every study respectively

10

Prometa 3 (Supplementary material method 3). For every incidence and mortality rate, the
RR-P was not significantly influenced by omitting any single study.

208 **3. Discussion** 

209 The objective of this review was to help us to estimate the burden of COVID-19 associated 210 with TB in SSA; the meta analysis including twenty studies and 191, 250 COVID-19 211 infected cases demonstrated that the overall pooled incidence proportion was 3% [2%-5%]. 212 Our COVID-19/TB incidence was higher than the incidence found in a recent meta-analysis 213 of forty-three studies which showed the pooled estimate for the proportion of active PTB was 214 1.07% [0.81%-1.36%] [42]. This systematic review included more studies conducted in low 215 and moderate TB prevalence compared to our review which included studies in high-burden 216 TB countries in SSA. Additionally, this review only included active PTB associated with 217 COVID-19, compared to our study which included COVID-19 cases with previous and/or 218 active TB.

219 The case fatality rate of COVID-19/TB including nine studies and 11,480 COVID-19 deaths 220 was 13% [4%-23%]. However, the meta-analysis of subgroup analysis (clinical vs post-221 mortem TB diagnostics) showed post-mortem PTB diagnostic counted higher case fatality 222 rate than clinical PTB diagnostic with 25% [3%-47%] for post-mortem TB diagnostic 223 compared to 7% [1%-12%] for PTB clinical diagnostic. Our case fatality rate was higher than 224 a meta-analysis including seventeen studies with 42,321 COVID-19 patients, of whom 632 225 (1.5%) had TB, reported on deaths due to COVID-19 [42]. Our high case fatality rate may be 226 justified by the same reasons referred to COVID-19/TB incidence. Interestingly, our review 227 has shown that TB was among the most common co-morbidity in COVID-19 patients in 228 SSA. This is consistent with findings in other studies including high TB post-mortem 229 diagnostic in SSA [43, 44]. Referring to a meta-analysis showing that TB exposure was in the

11

high-risk COVID-19 group (OR 1.67, 95% CI 1.06–2.65) [8]. COVID-19/TB clinical
diagnostic may be underestimated in SSA as post-mortem TB diagnostic has shown a high
mortality rate. Tamuzi et al. have suggested an algorithm for suspected COVID-19/TB
diagnostic in high-burden HIV/TB countries [8]. This algorithm may reflect the true COVID19/TB incidence in high-burden TB countries and reduce COVID-19/TB severity rate OR
4.50 (95% CI 1.12–18.10) and mortality (OR 2.23, 95% CI 1.83–2.74) compared to non-TB
group [8].

This deleterious synergism of SARS-CoV-2 and Mycobacterium tuberculosis increases the 237 238 risk of COVID-19-associated morbidity and mortality [8], and patients with PTB may increase the severity of COVID-19 and death due to chronic lung disease and 239 240 immunosuppression. In fact, advanced PTB is characterized by significant collagen 241 deposition and fibrosis [45-46], although tissue remodelling during fibrosis is a healing 242 process, extensive fibrosis with scar formation impairs lung function [47]. A study reported a 243 series of 454 cases of massive fibrosis with evidence of TB in 40% [48]. Furthermore, 244 Angiotensin-converting enzyme 2 (ACE2) has been reported to play a protective role in lung 245 fibrosis [49]. In lung biopsy specimens of patients with lung fibrosis, ACE2 messenger RNA 246 (mRNA) and enzyme activity decreased significantly [49, 50]. Interestingly, SARS-CoV-2 247 spike protein decreases the amount of ACE2 expression during viral infection [51]. 248 Decreased ACE2 expression results in increased Angiotensin II (ANG-II) levels and 249 contributes to lung fibrosis and pulmonary failure [49]. In three different acute lung injury 250 models, loss of ACE2 expression precipitated serious acute lung failure, while recombinant 251 human ACE2 (RhACE2) attenuated acute respiratory distress syndrome (ARDS) and further 252 decreased ANG-II levels in the lungs [52, 53]. In addition to transforming growth factor beta 253 (TGF- $\beta$ ), and ACE2, other pathways can contribute to SARS-CoV-2 mediated lung fibrosis. 254 Monocyte chemoattractant protein 1 (MCP-1) is a chemokine that causes lung fibrosis. In

12

255 addition, there are permanent changes in lung architecture after TB due, in part, to aberrant 256 wound-healing processes [54]. Regulation of the TGF- $\beta$  signalling pathway was also 257 associated with elevated levels of collagen in lung lesions prior to and during TB [54, 55]. 258 The TGF- $\beta$  activation pathways in both SARS-CoV-2 and PTB contribute to the production 259 of fibrin, collagen, and secreted proteases (Matrix metalloproteinases) associated with human 260 cavities involved in the formation of fibrosis and tissue remodelling [47]. In summary, the 261 presence of cavitary lesions, fibrosis, and extensive lung pathology was then identified as a 262 major risk factor for poor COVID-19/TB outcomes, which could be explained by reduced 263 drug penetration due to minimal blood supply in fibrotic lung sites [56]. This is consistent 264 with our study findings, which revealed that previous TB had the highest incidence 265 proportion and case fatality rate among COVID-19 when compared to current TB. In fact, 266 previous TB patients may be more prone to cavitary lesions, fibrosis, and extensive lung 267 pathology. Lastly, the transient immunosuppression characterized both COVID-19 and 268 current TB, a reason for poorer IgG antibody response and a delayed viral clearance in co-269 infected SARS-CoV-2 patients, and the use of corticoid therapy in SARS-CoV-2 added even 270 more on immunosuppression [8]. This could be explained by significant cases of current TB 271 who are likely on TB treatment or were latent TB infection (LTBI) among HIV-infected 272 cases included in the pooled result of the current TB studies by Jassat et al., 2020; Boulle et 273 al., 2020; and Parker et al., 2020 (Supplementary Table 1).

There are several implications to our findings in screening TB concomitantly to COVID-19 in SSA. Our findings indicate that the risks of COVID-19 associated with previous and/or current TB may be underestimated in SSA, as this co-infection is poorly reported. Although there is a paucity of accurate epidemiological data about COVID-19 associated with previous and/or current TB, the fatality rate is estimated high. Therefore, COVID-19 associated with TB should be taken in the context of proper history taking, accurate diagnostic tools, and

13

clear management [8]. Then, clinicians dealing with a possible SARS-CoV-2 patient from a
high-burden TB region should never forget TB as a coexisting pathology.

282 There was substantial variation between studies that looked at the incidence and case fatality 283 rates. This heterogeneity can be explained by a model that includes cumulative COVID-19 284 cases, HIV prevalence, and TB incidence, all of which vary significantly across countries. 285 Meta-regression revealed statistically significant p-values for the relationship between effect 286 size and our model. Furthermore, the RR-P was not significantly influenced by omitting any 287 single study in a sensitivity analysis performed by sequentially omitting every study for every 288 incidence and mortality rate. To assess publication bias quantitatively and qualitatively, 289 Egger's and Mazumdar's rank correlation test and Begg's funnel plot were used. Asymmetry 290 was found in the plot that included the COVID-19/TB incidence proportion (Fig 7). Because 291 the P-values of both tests for COVID-19/TB incidence rate were (-1.10, P = 0.285) and (-1.10, P = 0.285)292 0.26, P = 0.795), respectively, neither Egger's nor Mazumdar's rank correlation tests showed 293 obvious publication bias in different studies included in the review. Furthermore, the P-values 294 for [Egger's test (t = 0.49, p = 0.642)] 0.173 and [Begg and Mazumdar's rank correlation test 295 (z = -0.83, p = 0.404) for COVID-19/TB mortality rate were 0.173 and 0.404, respectively.

296 Our systematic review is limited by the quality of the included studies: first, the majority 297 involved retrospective data analyses, which increase the risk of bias associated with the 298 recording of baseline data, the need for imputation, and potential selection bias. Retrospective 299 studies did not report how missing data were managed or if imputation was used. 300 Considerable risk of selection bias was noted in retrospective and cross-sectional studies. 301 Finally, the results of the case fatality meta analysis should be interpreted with caution 302 because data pooling the post-mortem PTB diagnostic and previous TB were all extracted in 303 studies conducted in Zambia [13, 37-39] and South Africa [16, 26], respectively. This could 304 limit the external validity of the review. Future studies should be meticulously designed with

14

high quality and systematic methods of PTB diagnostic associated with COVID-19. This
will play a substantial role in reflecting the true incidence and mortality rates of COVID19/TB in SSA. Furthermore, post-COVID pulmonary fibrosis (PCPF) or long COVID-19related interstitial lung disease (LC-ILD) associated with current or previous TB requires
more attention and research in high HIV/TB burden regions such as SSA.

#### 310 **4. Conclusion**

311 This is a systematic review of the incidence proportion and case fatality rate of COVID-19 312 associated with tuberculosis in SSA. This study found that the incidence of tuberculosis 313 associated with COVID-19 is higher in SSA than in the rest of the world, as are the case 314 fatality rates. Previous TB among COVID-19 patients had the highest incidence proportion 315 and case fatality rates. However, due to the lack of specific COVID-19/TB diagnostic tools, 316 COVID-19 associated with PTB may be underreported in studies conducted in SSA. This is 317 supported by the high case fatality rate of COVID-19/TB in post-mortem diagnostic. Large-318 scale cohort studies with a sufficiently clear tool on previous and/or current PTB diagnostic 319 tools are required to confirm COVID-19/TB incidence and case fatality.

320

321

#### 322 **5.** Abbreviations

ACE2: Angiotensin-Converting Enzyme 2; ARDS: Acute respiratory distress syndrome; COVID-19: Coronavirus disease 2019; HIV: human immunodeficiency virus; LC-ILD: long COVID-19-related interstitial lung disease; MCP-1: Monocyte Chemoattractant Protein-1; mRNA: messenger RNA; NOS: Newcastle-Ottawa scale; PCPF: post-COVID pulmonary fibrosis; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PTB: pulmonary tuberculosis; SSA: sub-Saharan Africa; SARS-CoV-2: Severe acute

329	respiratory sy	ndrome	coronavirus	2;	TB:	tuberculosis;	TGF-β:	transforming	growth	factor;

330 WHO: World Health Organization;

#### **6.** Footnotes

- 332 Contributions: JLT conceived the study and developed the protocol. JLT did the literature
- search and selected the studies. JLT and GL reviewed the methodological quality of the study
- and extracted the relevant information. JLT synthesized the data. JLT wrote the first draft of
- the paper. GL and PB revised successive drafts of the paper. PSN supervised the review
- 336 steps. All the authors approved its final version. JLT is the guarantor of the study.
- 337 Ethics approval and consent to participate: Not required.
- 338 **Consent for publication:** Not applicable.

339 Competing interests: None of the authors in this study have any conflict of interest340 regarding the publication of the paper.

- 341 **7. References**
- WHO. COVID-19 Weekly Epidemiological Update, Edition 119 published 23
   November 2022.
- Candido DDS, Watts A, Abade L, Kraemer MUG, Pybus OG, Croda J, Oliveira W,
   Khan K, Sabino EC, Faria NR. Routes for COVID-19 importation in Brazil. J Trav
   Med 2020; 27: taaa042.
- 347 3. World Health Organization, Electronic State Parties Self-Assessment Annual
  348 Reporting Tool (e-SPAR), 2019. Available at: https://extranet.who.int/e-spar.
- Skrip LA, Selvaraj P, Hagedorn B, Ouédraogo AL, Noori N, Orcutt A, Mistry D,
   Bedson J, Hébert-Dufresne L, Scarpino SV, Althouse BM. Seeding COVID-19 across

351		Sub-Saharan Africa: An Analysis of Reported Importation Events across 49
352		Countries. Am J Trop Med Hyg. 2021;104(5):1694–702.
353	5.	Chintalapudi N, Battineni G, Amenta F. COVID-19 virus outbreak forecasting of
354		registered and recovered cases after sixty-day lockdown in Italy: a data driven model
355		approach. J Microbiol Immunol Infect 2020;53: 396–403.
356	6.	Chen Y, Li Z, Zhang YY, Zhao YH, Yu ZY. 2020. Maternal health care management
357		during the outbreak of coronavirus disease 2019. J Med Virol 92: 731–739.
358	7.	Bell D, Hansen KS, Kiragga AN, Kambugu A, Kissa J, Mbonye AK. Predicting the
359		Impact of COVID-19 and the Potential Impact of the Public Health Response on
360		Disease Burden in Uganda. Am J Trop Med Hyg. 2020;103(3):1191-1197.
361	8.	Tamuzi JL, Ayele BT, Shumba CS, Adetokunboh OO, Uwimana-Nicol J, Haile ZT,
362		Inugu J, Nyasulu PS. Implications of COVID-19 in high burden countries for
363		HIV/TB: A systematic review of evidence. BMC Infect Dis. 2020;20(1):744.
364	9.	WHO.GlobalTuberculosisreport,2020.
365		https://www.who.int/tb/publications/global_report/TB20_Exec_Sum_20201014.pdf
366	10	. Kuupiel D, Vezi P, Bawontuo V, Osei E, Mashamba-Thompson TP. Tuberculosis
367		active case-finding interventions and approaches for prisoners in sub-Saharan Africa:
368		a systematic scoping review. BMC Infect Dis. 2020;20(1):570.
369	11	. Chen Y, Wang Y, Fleming J, Yu Y, Gu Y, Liu C, Fan L, Wang X, Cheng M, Bi L,
370		Liu Y. Active or latent tuberculosis increases susceptibility to COVID-19 and disease
371		severity. https://www.medrxiv.org/content/10.1101/2020.03.10.20033795v1.full.pdf

17

372

12. Udwadia ZF, Vora A, Tripathi AR, Malu KN, Lange C, Sara Raju R. COVID-19 -

373	Tuberculosis interactions: When dark forces collide. Indian J Tuberc. 2020;67(4S):
374	S155-S162.
375	13. Mwananyanda L, Gill CJ, MacLeod W, Kwenda G, Pieciak R, Mupila Z, Lapidot R,
376	Mupeta F, Forman L, Ziko L, Etter L, Thea D. Covid-19 deaths in Africa: prospective
377	systematic postmortem surveillance study. BMJ. 2021;372: n334.
378	14. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-
379	Neino MM, Bernard PV, Biala JS, Blanc FX, Bogorodskaya EM, Borisov S,
380	Buonsenso D, Calnan M, Castellotti PF, Centis R, Chakaya JM, Cho JG, Codecasa
381	LR, D'Ambrosio L, Denholm J, Enwerem M, Ferrarese M, Galvão T, García-
382	Clemente M, García-García JM, Gualano G, Gullón-Blanco JA, Inwentarz S, Ippolito
383	G, Kunst H, Maryandyshev A, Melazzini M, de Queiroz Mello FC, Muñoz-Torrico
384	M, Njungfiyini PB, Palmero DJ, Palmieri F, Piccioni P, Piubello A, Rendon A, Sabriá
385	J, Saporiti M, Scognamiglio P, Sharma S, Silva DR, Souleymane MB, Spanevello A,
386	Tabernero E, Tadolini M, Tchangou ME, Thornton ABY, Tiberi S, Udwadia ZF,
387	Sotgiu G, Ong CWM, Goletti D. Worldwide Effects of Coronavirus Disease
388	Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis.
389	2020;26(11):2709-2712.
390	15. Mousquer GT, Peres A, Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection:
391	The phantom menace. Tuberculosis (Edinb). 2021; 126:102020.
392	16. Western Cape Department of Health in collaboration with the National Institute for
393	Communicable Diseases, South Africa. Risk Factors for Coronavirus Disease 2019

- 394 (COVID-19) Death in a Population Cohort Study from the Western Cape Province,
- 395 South Africa. Clin Infect Dis. 2021;73(7): e2005-e2015.

396	17. Nachega JB, Isł	ioso DK, Otokoye JO,	Hermans MP, Macheka	no RN, Sam-Agudu
397	NA, Bongo-Pasi	Nswe C, Mbala-Kinge	beni P, Madinga JN, Mu	ukendi S, Kolié MC,
398	Nkwembe EN,	Mbuyi GM, Nsio JM,	Mukeba Tshialala D,	Tshiasuma Pipo M,
399	Ahuka-Mundeke	S, Muyembe-Tamfum	JJ, Mofenson L, Smith	G, Mills EJ, Mellors
400	JW, Zumla A,	Mavungu Landu DJ,	Kayembe JM. Clinical	Characteristics and
401	Outcomes of Par	ients Hospitalized for C	COVID-19 in Africa: Ea	rly Insights from the
402	Democratic Rep	ublic of the Congo. Am	J Trop Med Hyg. 2020;1	03(6):2419-2428.
403	18. van der Zalm M	M, Lishman J, Verhager	n LM, Redfern A, Smit I	., Barday M, Ruttens
404	D, da Costa A,	van Jaarsveld S, Itana J	, Schrueder N, Van Scha	llkwyk M, Parker N,
405	Appel I, Fourie	B, Claassen M, Work	man JJ, Goussard P, V	an Zyl G, Rabie H.
406	Clinical Experies	nce with Severe Acute I	Respiratory Syndrome C	oronavirus 2-Related
407	Illness in Childre	en: Hospital Experience	in Cape Town, South Af	rica. Clin Infect Dis.
408	2021;72(12): e93	38-e944.		
409	19. Kirenga B, Mutt	amba W, Kayongo A, N	Isereko C, Siddharthan T	r, Lusiba J, Mugenyi
410	L, Byanyima RI	K, Worodria W, Nakwa	agala F, Nantanda R, Ki	muli I, Katagira W,
411	Bagaya BS, Nas	inghe E, Aanyu-Tukam	uhebwa H, Amuge B, Se	ekibira R, Buregyeya
412	E, Kiwanuka N	Muwanga M, Kalung	i S, Joloba ML, Kateete	e DP, Byarugaba B,
413	Kamya MR, M	webesa H, Bazeyo W	. Characteristics and ou	tcomes of admitted
414	patients infected	with SARS-CoV-2 in	Uganda. BMJ Open Re	espir Res. 2020;7(1):
415	e000646.			
416	20. Gebrecherkos T,	Gessesse Z, Kebede Y,	Gebreegzabher A, Tasse	w G, Abdulkader M,
417	Ebuy H, Desta A	, Hailu A, Harris V, de	Wit TR. Effect of co-inf	fection with parasites
418	on	severity	of	COVID-19.
419	https://www.med	lrxiv.org/content/10.110	01/2021.02.02.21250995v	71

420	21. Zamparini J, Venturas J, Shaddock E, Edgar J, Naidoo V, Mahomed A, Mer M, Bolon
421	S, Smith O, Motara F, Laher A. Clinical characteristics of the first 100 COVID-19
422	patients admitted to a tertiary hospital in Johannesburg, South Africa. Wits Journal of
423	Clinical Medicine. 2020;2(2):105-14.
424	22. Otuonye NM, Olumade TJ, Ojetunde MM, Holdbrooke SA, Ayoola JB, Nyam IY,
425	Iwalokun B, Onwuamah C, Uwandu M, Abayomi A, Osibogun A, Bowale A,
426	Osikomaiya B, Thomas B, Mutiu B, Odunukwe NN. Clinical and Demographic
427	Characteristics of COVID-19 patients in Lagos, Nigeria: A Descriptive Study. J Natl
428	Med Assoc. 2021;113(3):301-306.
429	23. Parker A, Koegelenberg CFN, Moolla MS, Louw EH, Mowlana A, Nortjé A, Ahmed
430	R, Brittain N, Lalla U, Allwood BW, Prozesky H, Schrueder N, Taljaard JJ. High
431	HIV prevalence in an early cohort of hospital admissions with COVID-19 in Cape
432	Town, South Africa. S Afr Med J. 2020;110(10):982-987.
433	24. Sebastião CS, Neto Z, Martinez P, Jandondo D, Antonio J, Galangue M, de Carvalho
434	M, David K, Miranda J, Afonso P, Inglês L, Carrelero RR, de Vasconcelos JN,
435	Morais J. Sociodemographic characteristics and risk factors related to SARS-CoV-2
436	infection in Luanda, Angola. PLoS One. 2021;16(3): e0249249.
437	25. du Bruyn E, Stek C, Daroowala R, Said-Hartley Q, Hsiao M, Goliath RT, Abrahams
438	F, Jackson A, Wasserman S, Allwood B, Davis AG. Communicable and non-
439	communicable co-morbidities and the presentation of COVID-19 in an African setting
440	of high HIV-1 and tuberculosis prevalence.
441	https://www.medrxiv.org/content/medrxiv/early/2021/05/11/2021.05.11.21256479.ful
442	l.pdf

20

443	26. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, Murangandi P,
444	Savulescu D, Walaza S, Bam JL, Davies MA. COVID-19 in-hospital mortality in
445	South Africa: The intersection of communicable and non-communicable chronic
446	diseases in a high HIV prevalence setting, 2020.
447	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3783089
448	27. Hassan Z, Hashim MJ, Khan G. Population risk factors for COVID-19 deaths in
449	Nigeria at sub-national level. Pan Afr Med J. 2020;35(Suppl 2):131.
450	28. Hesse R, van der Westhuizen DJ, George JA. COVID-19-Related Laboratory Analyte
451	Changes and the Relationship Between SARS-CoV-2 and HIV, TB, and HbA1c in
452	South Africa. Adv Exp Med Biol. 2021; 1321:183-197.
453	29. Ombajo LA, Mutono N, Sudi P, Mutua M, Sood M, Loo AM, Juma P, Odhiambo J,
454	Shah R, Wangai F, Maritim M. Epidemiological and clinical characteristics of
454 455	Shah R, Wangai F, Maritim M. Epidemiological and clinical characteristics ofCOVID-19patientsinKenya.
455	COVID-19 patients in Kenya.
455 456	COVID-19patientsinKenya.https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1
455 456 457	COVID-19       patients       in       Kenya.         https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1       30. Abayomi A, Osibogun A, Kanma-Okafor O, Idris J, Bowale A, Wright O, Adebayo
455 456 457 458	COVID-19patientsinKenya.https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v130. Abayomi A, Osibogun A, Kanma-Okafor O, Idris J, Bowale A, Wright O, AdebayoB, Balogun M, Ogboye S, Adeseun R, Abdus-Salam I, Mutiu B, Saka B, Lajide D,
455 456 457 458 459	<ul> <li>COVID-19 patients in Kenya. https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1</li> <li>30. Abayomi A, Osibogun A, Kanma-Okafor O, Idris J, Bowale A, Wright O, Adebayo B, Balogun M, Ogboye S, Adeseun R, Abdus-Salam I, Mutiu B, Saka B, Lajide D, Yenyi S, Agbolagorite R, Onasanya O, Erinosho E, Obasanya J, Adejumo O, Adesola</li> </ul>
455 456 457 458 459 460	<ul> <li>COVID-19 patients in Kenya. https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1</li> <li>30. Abayomi A, Osibogun A, Kanma-Okafor O, Idris J, Bowale A, Wright O, Adebayo B, Balogun M, Ogboye S, Adeseun R, Abdus-Salam I, Mutiu B, Saka B, Lajide D, Yenyi S, Agbolagorite R, Onasanya O, Erinosho E, Obasanya J, Adejumo O, Adesola S, Oshodi Y, Akase IE, Ogunbiyi S, Omosun A, Erinoso F, Abdur-Razzaq H, Osa N,</li> </ul>
455 456 457 458 459 460 461	<ul> <li>COVID-19 patients in Kenya. https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1</li> <li>30. Abayomi A, Osibogun A, Kanma-Okafor O, Idris J, Bowale A, Wright O, Adebayo B, Balogun M, Ogboye S, Adeseun R, Abdus-Salam I, Mutiu B, Saka B, Lajide D, Yenyi S, Agbolagorite R, Onasanya O, Erinosho E, Obasanya J, Adejumo O, Adesola S, Oshodi Y, Akase IE, Ogunbiyi S, Omosun A, Erinoso F, Abdur-Razzaq H, Osa N, Akinroye K. Morbidity and mortality outcomes of COVID-19 patients with and</li> </ul>
455 456 457 458 459 460 461 462	<ul> <li>COVID-19 patients in Kenya. https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1</li> <li>30. Abayomi A, Osibogun A, Kanma-Okafor O, Idris J, Bowale A, Wright O, Adebayo B, Balogun M, Ogboye S, Adeseun R, Abdus-Salam I, Mutiu B, Saka B, Lajide D, Yenyi S, Agbolagorite R, Onasanya O, Erinosho E, Obasanya J, Adejumo O, Adesola S, Oshodi Y, Akase IE, Ogunbiyi S, Omosun A, Erinoso F, Abdur-Razzaq H, Osa N, Akinroye K. Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study. Glob Health Res</li> </ul>

466 TR, Wolday D. Clinical features, and risk factors associated with morbidity and

21

467	mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;
468	105:776-783.
469	32. Bepouka BI, Mandina M, Makulo JR, Longokolo M, Odio O, Mayasi N, Pata T,
470	Nsangana G, Tshikangu F, Mangala D, Maheshe D, Nkarnkwin S, Muamba J, Ndaie
471	G, Ngwizani R, Yanga Y, Nkodila A, Keke H, Kokusa Y, Lepira F, Kashongwe I,
472	Mbula M, Kayembe JM, Situakibanza H. Predictors of mortality in COVID-19
473	patients at Kinshasa University Hospital, Democratic Republic of the Congo, from
474	March to June 2020. Pan Afr Med J. 2020; 37:105.
475	33. Ibrahim OR, Suleiman BM, Abdullahi SB, Oloyede T, Sanda A, Gbadamosi MS,
476	Yusuf BO, Iliyasu RY, Ibrahim LM, Danladi Dawud A, Bashir SS, Okonta NE, Umar
477	WF, Tekobo AG, Abubakar MS, Aminu BT, Ibrahim SO, Olaosebikan R, Mokuolu
478	OA. Epidemiology of COVID-19 and Predictors of Outcome in Nigeria: A Single-
479	Center Study. Am J Trop Med Hyg. 2020;103(6):2376-2381.
480	34. Mash RJ, Presence-Vollenhoven M, Adeniji A, Christoffels R, Doubell K, Eksteen L,
481	Hendrikse A, Hutton L, Jenkins L, Kapp P, Lombard A, Marais H, Rossouw L, Stuve
482	K, Ugoagwu A, Williams B. Evaluation of patient characteristics, management, and
483	outcomes for COVID-19 at district hospitals in the Western Cape, South Africa:

descriptive observational study. BMJ Open. 2021;11(1): e047016.

35. Chanda D, Minchella PA, Kampamba D, Itoh M, Hines JZ, Fwoloshi S, Boyd MA,
Hamusonde K, Chirwa L, Nikoi K, Chirwa R, Siwingwa M, Sivile S, Zyambo KD,
Mweemba A, Mbewe N, Mutengo KH, Malama K, Agolory S, Mulenga LB. COVID19 Severity and COVID-19-Associated Deaths Among Hospitalized Patients with
HIV Infection - Zambia, March-December 2020. MMWR Morb Mortal Wkly Rep.
2021;70(22):807-810.

491	36. Pillay-van Wyk V, Bradshaw D, Groenewald P, Seocharan I, Manda S, Roomaney
492	RA, Awotiwon O, Nkwenika T, Gray G, Buthelezi SS, Mkhize ZL. COVID deaths in
493	South Africa: 99 days since South Africa's first death. S Afr Med J.
494	2020;110(11):1093-1099.
495	37. Mudenda V, Mumba C, Pieciak RC, Mwananyanda L, Chimoga C, Ngoma B, Mupila
496	Z, Kwenda G, Forman L, Lapidot R, MacLeod WB, Thea DM, Gill CJ.
497	Histopathological Evaluation of Deceased Persons in Lusaka, Zambia with or Without
498	Coronavirus Disease 2019 (COVID-19) Infection: Results Obtained from Minimally
499	Invasive Tissue Sampling. Clin Infect Dis. 2021;73(Suppl_5): S465-S471.
500	38. Mucheleng'anga LA, Telendiy V, Hamukale A, Shibemba AL, Zumla A, Himwaze
501	CM. COVID-19 and Sudden Unexpected Community Deaths in Lusaka, Zambia,
502	Africa - A Medico-Legal Whole-Body Autopsy Case Series. Int J Infect Dis. 2021;
503	109:160-167.
504	39. Himwaze CM, Telendiy V, Maate F, Mupeta S, Chitalu C, Chanda D, Julius P,
505	Mumba C, Marimo C, Hamukale A, Mulenga L, Shibemba AL, Zumla A,
506	Mucheleng'anga LA. Post-mortem examination of Hospital Inpatient COVID-19
507	Deaths in Lusaka, Zambia - A Descriptive Whole-body Autopsy Series. Int J Infect
508	Dis. 2021; 108:363-369.
509	40. UNAIDS. UNAIDS data 2021.
510	https://www.unaids.org/en/resources/documents/2021/2021_unaids_data
511	41. WHO. Global Tuberculosis Report 2021. https://www.who.int/teams/global-
512	tuberculosis-programme/tb-reports/global-tuberculosis-report-2021


513	42. Aggarwal AN, Agarwal R, Dhooria S, Prasad KT, Sehgal IS, Muthu V. Active
514	pulmonary tuberculosis and coronavirus disease 2019: A systematic review and meta-
515	analysis. PLoS One. 2021;16(10): e0259006.
516	43. Bates M, Mudenda V, Shibemba A, Kaluwaji J, Tembo J, Kabwe M, Chimoga C,
517	Chilukutu L, Chilufya M, Kapata N, Hoelscher M, Maeurer M, Mwaba P, Zumla A.
518	Burden of tuberculosis at postmortem in inpatients at a tertiary referral centre in sub-
519	Saharan Africa: a prospective descriptive autopsy study. Lancet Infect Dis.
520	2015;15(5):544-51.
521	44. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-
522	mortem studies of HIV-infected adults and children in resource-limited settings: a
523	systematic review and meta-analysis. AIDS. 2015;29(15):1987-2002.
524	45. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical
525	review. Tuberculosis (Edinburgh, Scotland) 2011;91(6):497-509.
526	46. Subbian S, Tsenova L, Kim MJ, Wainwright HC, Visser A, Bandyopadhyay N,
527	Bader JS, Karakousis PC, Murrmann GB, Bekker LG, Russell DG, Kaplan G. Lesion-
528	Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis:
529	A Pilot Study. PLoS One. 2015;10(7): e0132249.
530	47. Tsenova L, Singhal A. Effects of host-directed therapies on the pathology of
531	tuberculosis. The Journal of pathology 2020; <u>https://doi.org/10.1002/path.5407</u> .
532	48. Rivers D, James WRL, Davies DG, Thomson S. The prevalence of tuberculosis at
533	necropsy in progressive massive fibrosis of coalworkers. British journal of industrial
534	medicine 1957; 14(1):39.

535	49. Zuo W, Zhao X, Chen Y-G. SARS Coronavirus and Lung Fibrosis. In: Molecular
536	Biology of the SARS-Coronavirus. Springer, 2010:247-58.

- 537 50. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin
  538 converting enzyme-2 is protective but downregulated in human and experimental lung
  539 fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology
  540 2008; 295(1): L178-85.
- 51. Kuba K, Imai Y, Rao S, Gao H, Guo, F., Guan B, Huan Y, Yang P, Zhang Y, Deng,
  W. and Bao, L., 2005. A crucial role of angiotensin converting enzyme 2 (ACE2) in
  SARS coronavirus–induced lung injury. Nature medicine 2005, 11(8): 875-879.
- 52. Imai Yumiko, Kuba Keiji, Rao Shuan, Huan Yi, Guo Feng, Guan Bin, et al.
  Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature
  2005;436(7047):112-6.
- 53. Sarzani R, Giulietti F, Di PC, Giordano P, Spannella F. The Pathophysiology of
  COVID-19 and SARS-CoV-2 Infection: Disequilibrium between the classic reninangiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
  American Journal of Physiology-Lung Cellular and Molecular Physiology
  2020;319(2): L325.
- 552 54. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage:
  553 from epidemiology to pathophysiology. European respiratory review: an official
  554 journal of the European Respiratory Society 2018; 27:147.
- 55. DiFazio RM, Mattila JT, Klein EC, Cirrincione LR, Howard M, Wong EA, et al.
  Active transforming growth factor-beta is associated with phenotypic changes in
  granulomas after drug treatment in pulmonary tuberculosis. Fibrogenesis & amp;
  tissue repair 2016; 9:6.

25

- 559 56. Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE
- 560 3rd, Zimmerman M, Dartois V, Savic RM. Tuberculosis drugs' distribution and
- 561 emergence of resistance in patient's lung lesions: A mechanistic model and tool for
- regimen and dose optimization. PLoS Med. 2019;16(4): e1002773.



**Figure 1:** Flow chart of PTB incidence and mortality proportions associated to COVID-19 in Sub-Saharan Africa





Figure 2: Distribution of included studies in Sub-Saharan African countries

Study ID		Effect Size with 95% Cl	Weight (%)
Jassat et al., 2020		0.04 [ 0.04, 0.04]	5.68
Boulle et al., 2020		0.10 [ 0.09, 0.10]	5.66
Hassan et al., 2020		0.03 [ 0.03, 0.03]	5.68
Nachega et al., 2020		0.03 [ 0.01, 0.04]	5.51
Zamparini et al., 2020		0.02 [ -0.01, 0.05]	4.80
van der Zalm et al., 2020	· ·	0.01 [ -0.00, 0.03]	5.29
Hesse et al., 2020		0.00 [ 0.00, 0.00]	5.68
Kirenga et al., 2020		0.02 [ -0.02, 0.05]	4.39
Otuonye et al., 2020	- <b></b> -	0.01 [ -0.00, 0.03]	5.27
Mash et al., 2021		0.06 [ 0.05, 0.07]	5.47
Parker et al., 2020	— <b>—</b>	0.12 [ 0.06, 0.17]	3.07
Ombajo et al., 2020		0.01 [ 0.00, 0.02]	5.62
Osibogun et al., 2021		0.00 [ 0.00, 0.01]	5.68
Abraha et al., 2021		0.00 [ 0.00, 0.01]	5.68
Bepouka et al., 2020		0.01 [ -0.01, 0.02]	5.43
Sebastião et al., 2021		0.01 [ -0.01, 0.03]	5.07
Ibrahim et al., 2020		0.04 [ -0.02, 0.11]	2.91
Gebrecherkos et al., 2021		0.00 [ -0.00, 0.01]	5.66
Du Bruyn et al., 2021		0.21 [ 0.13, 0.29]	2.26
Chanda et al., 2021		0.05 [ 0.03, 0.07]	5.19
Overall	•	0.03 [ 0.02, 0.05]	
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 99.76\%$ , $H^2 = 414.78$			
Test of $\theta_i = \theta_i$ : Q(19) = 3737.83, p = 0.00			
Test of $\theta = 0$ : $z = 4.03$ , $p = 0.00$			
	0 .1 .2		
Random-effects REML model			

Figure 3: pooled incidence proportion of COVID-19 associated with PTB in sub-Saharan

Africa

Study					Effect Size with 95% Cl			Weight (%)
Current and past TB								
Jassat et al., 2020					0.1	0 [ 0.09,	0.11]	10.00
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	+				0.1	0[ 0.09	0.11]	
Test of $\theta_i = \theta_i$ : Q(0) = -0.00, p = .								
Previous TB								
Jassat et al., 2020					0.2	1 [ 0.19	0.22]	10.00
Boulle et al., 2020					0.8	0 [ 0.76	0.84]	9.95
Mash et al., 2021					0.4	4 [ 0.33,	0.55]	9.50
Parker et al., 2020			-		0.3	5 [ 0.01,	0.69]	6.57
Heterogeneity: τ <sup>2</sup> = 0.07, 1 <sup>2</sup> = 99.24%, H <sup>2</sup> = 130.99	-	-			0.4	6 [ 0.19,	0.73]	
Test of $\theta_i = \theta_i$ : Q(3) = 909.16, p = 0.00								
Current TB								
Jassat et al., 2020					0.0	7 [ 0.06	0.08]	10.0
Boulle et al., 2020					0.1	5 [ 0.14	0.17]	9.9
Nachega et al., 2020	-	-			0.2	5[ 0.14,	0.37]	9.4
Hesse et al., 2020					0.0	4 [ 0.04	0.04]	10.0
Mash et al., 2021	÷				0.1	7 [ 0.10,	0.23]	9.8
Parker et al., 2020					- 0.8	0 [ 0.30,	1.30]	4.7
Heterogeneity: $\tau^2 = 0.01$ , $I^2 = 99.39\%$ , $H^2 = 163.75$	•				0.1	4 [ 0.06,	0.22]	
Test of $\theta_1 = \theta_1$ : Q(5) = 230.06, p = 0.00								
Overall	<	>			0.2	8[ 0.13	0.43]	
Heterogeneity: $\tau^2 = 0.06$ , $I^2 = 99.91\%$ , $H^2 = 1142.47$								
Test of $\theta_i = \theta_i$ : Q(10) = 2371.86, p = 0.00								
Test of group differences: $Q_{ts}(2) = 8.27$ , p = 0.02								
	Ó	.5		1	1.5			
andom-effects REML model								



current PTB

Study					-	Effect Siz	-	We <mark>ig</mark> ht (%)
Clinical diagnosis								
Jassat et al., 2020					0.05	[ 0.04,	0.05]	10.63
Boulle et al., 2020					0.18	[ 0.15,	0.21]	10.51
Wyk et al., 2020					0.03	[ 0.03,	0.04]	10.62
Mash et al., 2021	-	-			0.13	0.08,	0.19]	10.27
Ombajo et al., 2020					0.01	[ -0.01,	0.03]	10.59
Nachega et al., 2020					0.02	[ -0.01,	0.05]	10.53
Heterogeneity: $\tau^2$ = 0.00, I <sup>2</sup> = 99.22%, H <sup>2</sup> = 128.19	•				0.07	[ 0.01,	0.12]	
Test of $\theta_i = \theta_j$ : Q(5) = 116.07, p = 0.00								
Postmortem diagnosis								
Mwananyanda et al., 2021		-	-		0.31	0.27,	0.36]	10.35
Himwaze et al., 2021		—			0.10	[ -0.01,	0.21]	9.26
Mucheleng'anga et al., 2021		_			0.05	[ -0.04,	0.14]	9.67
Mudenda et al., 2021				-	— <b>0</b> .57	0.39,	0.75]	7.57
Heterogeneity: $\tau^2 = 0.05$ , $I^2 = 95.60\%$ , $H^2 = 22.72$ Test of $\theta_i = \theta_j$ : Q(3) = 44.66, p = 0.00		-			0.25	[ 0.03,	0.47]	
Overall Heterogeneity: $\tau^2 = 0.02$ , $I^2 = 99.71\%$ , $H^2 = 347.79$ Test of $\theta_i = \theta_j$ : Q(9) = 275.43, p = 0.00	-	>			0.13	[ 0.04,	0.23]	
Test of group differences: $Q_b(1) = 2.44$ , $p = 0.12$								
Random-effects REML model	Ō	.2	.4	.6	.8			

Figure 5: pooled case fatality rate of COVID-19 associated with PTB in sub-Saharan Africa

Study					Weight (%)		
Current and past TB							
Jassat et al., 2020					0.01 [	0.01, 0.01]	14.78
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ , $H^2 = .$	•				0.01 [	0.01, 0.01]	
Test of $\theta_i = \theta_j$ : Q(0) = 0.00, p = .							
Previous TB							
Jassat et al., 2020					0.03 [	0.02, 0.03]	14.76
Boulle et al., 2020			_	-	0.14 [	0.11, 0.17]	13.36
Heterogeneity: $\tau^2 = 0.01$ , $I^2 = 98.47\%$ , $H^2 = 65.28$					<del>- 8:08</del> [	-0.03, 0.19]	
Test of $\theta_i = \theta_j$ : Q(1) = 65.28, p = 0.00							
Current TB							
Jassat et al., 2020					0.01 [	0.01, 0.01]	14.78
Boulle et al., 2020					0.04 [	0.03, 0.06]	14.28
Nachega et al., 2020		<u> </u>			0.02 [	-0.01, 0.05]	13.34
Wyk et al., 2020					0.03 [	0.03, 0.04]	14.69
Heterogeneity: $\tau^2$ = 0.00, I <sup>2</sup> = 93.01%, H <sup>2</sup> = 14.30	-				0.03 [	0.01, 0.04]	
Test of $\theta_1 = \theta_1$ : Q(3) = 62.09, p = 0.00							
Overall		$\sim$			0.04 [	0.01, 0.07]	
Heterogeneity: $T^2 = 0.00$ , $I^2 = 99.75\%$ , $H^2 = 392.73$					-	-	
Test of $\theta_i = \theta_j$ : Q(6) = 208.70, p = 0.00							
Test of group differences: $Q_b(2) = 4.02$ , p = 0.13							
	Ó	.05	.1	.15	-		
Random-effects REML model	-						

Figure 6: pooled case fatality rate of COVID-19 associated with current and previous PTB




Figure 7: Funnel plot of incidence proportion of COVID-19 associated with PTB in sub-

Saharan Africa